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ABSTRACT 
Purpose In a population-based sample of cervical cancer survivors health-related quality of life 
(HRQoL) was assessed 2-10 years post-diagnosis.  
Methods and Materials All patients diagnosed with cervical cancer in 1995-2003 in the Eindhoven 
region and alive after January 2006 were identified through the cancer registry. Generic HRQoL 
(SF-36, EQ-5D), cervical cancer-specific HRQoL (EORTC-QLQ-CX24), and anxiety (STAI-6) were 
assessed and compared with a reference population (n=349). Data on tumor characteristics at 
diagnosis and disease progression were available.  
Results A total of 291 women responded (69%), mean age 53 (SD 13, range 31-88) years. Treatment 
had consisted of surgery (n=195) or a combination of therapies (n=75); one woman had not been 
treated. Of all women, 85% was clinically disease free, 2% had a recurrence/metastasis and in 13% 
this was unknown. After controlling for background characteristics (age, education, job and marital 
status, having children, and country of birth) generic HRQoL scale scores were similar to the reference 
population, except for worse mental health among the survivors. The most frequent symptoms were 
crampy pain in the abdomen or belly (17%), urinary leakage (15%), menopausal symptoms (18%), 
and problems with sexual activity. Compared to the 6-10-year survivors, more sexual worry and worse 
body image were reported by the 2-5-year survivors. Compared to surgery only, especially primary 
radiotherapy was associated with an increased frequency of treatment-related side effects, also after 
controlling for age and disease stage at diagnosis and at follow-up.  
Conclusions Most of the cervical cancer survivors were coping well, although their mental health was 
worse than in the reference population. Even after 2-10 years, radiotherapy was associated with an 
increased frequency of treatment-related side effects.   
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Introduction 
Cervical cancer is an important cause of death in women, especially in developing countries. In 
Europe, 60,000 women are diagnosed with cervical cancer annually.1 Due to improved therapies and 
early detection the number of women that survive cervical cancer has increased.2 These survivors 
have been diagnosed with a life-threatening disease and were confronted with their own mortality. 
They may still experience the physical side effects of cervical cancer therapy such as permanent 
consequences for sexual function and childbearing, as well as menopausal, urological and 
gastrointestinal symptoms. 3 Survivors may also experience anxiety for recurrence of cervical cancer.  
Health-related quality of life (HRQoL), defined in this study as the quality of life relating to disease 
and/or treatment, has been described for the 1 to 5-6 years following treatment of cervical cancer.4-8 
In, for example, the case of prostate cancer 9 and in adult-onset cancers in general 10 long-term cancer 
survivors showed a comparatively favorable HRQoL, while HRQoL was less favorable among non-
Hodgkin survivors.11 With the exception of a recent Korean study12, long-term HRQoL after diagnosis 
of cervical cancer, however, has only been described for small numbers of patients.13-15  
The present study aimed to assess the generic and treatment-specific HRQoL of women who survived 
cervical cancer. For this, a population-based study was conducted among all women diagnosed with 
cervical cancer in the region of the Eindhoven Cancer Registry in the years 1995-2003. We 
hypothesized that HRQoL of survivors would be similar to the general population, that HRQoL would 
be better among long-term survivors than among short-term survivors, and that adjuvant radiotherapy 
after surgery would be associated with worse HRQoL than primary radiotherapy.  
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Methods 
Setting and respondents 
The Eindhoven Cancer Registry (ECR) records data on all newly diagnosed cancer patients in the 
south of the Netherlands, an area with 2.3 million inhabitants, 17 hospital locations, and two large 
radiotherapy institutes.16 In cooperation with the ECR and all gynecologic oncology departments in the 
region we conducted a population-based, cross-sectional survey. All women could be identified who 
were diagnosed with cervical cancer between 1 January 1995 and 31 December 2003 (n=691). 
Women who had died could be excluded through linkage with the Central Bureau for Genealogy that 
collects data on all deceased Dutch citizens. We identified 444 women (64%) who were still alive on 
31 January 2006 (Figure 1); of this group, 8 women were not contacted as advised by their physician 
e.g. because of serious (mental) illness, and 15 addresses could not be verified. The remaining 421 
survivors were sent a questionnaire by their (former) gynecologists. In the accompanying letter the 
women were asked to complete the questionnaire and were informed that, by returning the completed 
questionnaire, they consented to linkage of the questionnaire data with their disease history as 
registered by the ECR. Patients were assured that non-participation would have no consequences for 
their follow-up care or treatment. If the questionnaire was not returned within two months, a reminder 
letter with an additional copy of the questionnaire was sent. This study was part of a comprehensive 
evaluation of the Dutch cervical cancer screening program. The Ethics Committee of the Erasmus 
University Medical Center Rotterdam approved the research protocol.  
 
Respondents’ characteristics 
The ECR routinely collects data on tumor characteristics, including date of diagnosis, tumor grade and 
stage (Tumor-Lymph Node-Metastasis [TNM] clinical classification),17 treatment, and on date of birth 
and co-morbidity at the time of diagnosis (a slightly adapted version of the Charlson co-morbidity 
index).18 
Data on recurrences and/or metastasis were obtained through patient records of treating 
gynecologists and general physicians.  
Information on marital status, education, co-morbidity, profession, and country of birth was obtained 
through the questionnaire. Educational level was classified as low (primary school or lower technical 
education), intermediate, or high (college/university degree).  
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HRQoL of survivors compared with other groups 
To assess non-response bias, respondents’ data on tumor characteristics and primary therapies as 
registered by the ECR were compared with data of non-respondents. The latter group consisted of 
cervical cancer survivors who were alive on 31 January 2006, but did not complete the questionnaire, 
including women that had not been contacted because of ill health or unknown address.  
To enable a better interpretation of respondents’ generic HRQoL scores we included a reference 
group from the general population. Randomly selected women (aged 30-70 years, stratified in 10-year 
age groups) were sent a questionnaire through the regional screening organization in Maastricht. 
Overall response was 46%. Data from the first 349 questionnaires that randomly became available 
after data input were included in the analyses for the current study. 
The respondents’ data were compared with two more data sets: 
• For a comparison between survivors and non-survivors we present tumor characteristics and 
primary therapies of women who were diagnosed with cervical cancer in 1995-2003 and died 
before 31 January 2006; 
• To enable a better interpretation of respondents’ cervical cancer-specific HRQoL we use the 
validation study of the EORTC cervical cancer-specific module (QLQ-CX24).3  
Finally, two comparisons were made within the respondents group, i.e. between those who survived 
2-5 years vs. 6-10 years, and between those who received primary radiotherapy vs. surgery only vs. 
adjuvant radiotherapy after surgery.  
 
Questionnaire 
The questionnaire included validated measures on generic HRQoL, anxiety, cervical cancer-specific 
HRQoL and disease-related psychological distress.  
Generic HRQoL was assessed by the 36-item Short-Form Health Survey (SF-36) and the EuroQol 
classification (EQ-5D). The SF-36 consists of 8 multi-item scales in the physical, social, and mental 
domain. Higher scale scores (0-100) indicate better functioning.19 The EQ-5D classification consists of 
5 items (mobility, self-care, usual activities, pain/discomfort, and anxiety/ depression). Classification 
scores can be linked to a utility score with 0 indicating ‘death’ and 1 ‘full health’.20 The EQ-5D is 
complemented by a visual analog scale on current health, the Valuation of Own Health, which is 
  
 
8 
anchored at the lower end (0) by ‘worst imaginable health state’ and at the upper end (100) by ‘best 
imaginable health state’.  
Anxiety was assessed by the STAI-6, a validated short version of the State Trait Anxiety Inventory 
containing 6 items on feeling at ease or upset. Higher scores (20-80) indicate higher levels of 
anxiety.21, 22 A STAI-State score of over 44 defines an individual as highly anxious.23 
Disease-specific HRQoL was assessed through a recently validated cervical cancer-specific module 
(EORTC-QLQ-CX24), consisting of 3 multi-item scales on symptom experience, body image, and 
sexual/vaginal functioning and of 6 single-item scales. Higher scores (0-100) indicate worse 
functioning except for sexual activity and enjoyment.3  
Disease-related psychological distress of having (had) cervical cancer was assessed by the Impact of 
Events Scale (IES). This measure includes a 7-item scale on intrusion referring to the degree the 
respondent was overwhelmed by thoughts and feelings about cervical cancer, and an 8-item 
avoidance scale referring to the tendency to keep off these thoughts and feelings. By summation of 
the intrusion (0-35) and the avoidance score (0-40) the total distress score is obtained, with higher 
scores indicating higher levels of distress.24  
 
Statistical analysis 
All statistical analyses were performed using SPSS for Windows, version 15.0.  
Routinely collected data from the ECR on tumor characteristics enabled a comparison between 
respondents and non-respondents using Kruskall-Wallis non-parametric tests for continuous variables 
and Chi-square analyses for categorical variables. Procedures concerning imputation of missing 
responses in the SF-36 items were conducted according to the guidelines of the SF-36.19 General 
linear model (ANOVA) analyses were carried out to assess differences between respondents and the 
reference population.  
The minimal important difference (MID), defined as the smallest change in a patient-reported outcome 
that is perceived by patients as beneficial or that would result in a change of treatment, was 
operationalized as a difference of at least half a standard deviation.25  
General linear models were used to analyze the relation between time since diagnosis versus each of 
the 9 cervical cancer-specific subscales. General linear models that were used to analyze the relation 
between tumor characteristics and primary treatments versus HRQoL outcomes included age at 
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survey and disease stage at diagnosis and at follow-up. In all analyses p-values less than 0.05 
(referring to two-sided statistical tests) were considered significant.  
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Results 
Respondents’ characteristics 
Of the 421 cervical cancer survivors (response 69%), 291 completed the questionnaire. The remaining 
130 questionnaires were not completed due to wrong address (n=11), patients’ bad health (n=2), lack 
of motivation (n=2), death (n=1), or unknown reasons (n=114) (Figure 1). Compared to the reference 
group, survivors were older, had a lower education level, and lower rates of having paid jobs, having 
partners, and having children (Table 1).  
 
Clinical data 
The average age at diagnosis was 47 (range 25-83) years, average time since diagnosis was 6.6 
(range 2-11) years (Table 2). Initial therapy consisted of surgery only in 67% of respondents, whereas 
7% received radiotherapy only. The remaining patients were treated with a combination of surgery, 
radiotherapy, and/or chemotherapy, while one woman had not been treated. In April 2006, 85% of 
survivors were clinically disease free, 2% had metastasis and/or local recurrence, and in 13% it was 
unknown whether recurrence had occurred. Compared to respondents, non-respondents had a 
significantly worse TNM stage at diagnosis and more local recurrence at follow-up. Deceased patients 
were older at diagnosis than survivors. Furthermore, tumor grade and TNM stage at diagnosis were 
worse than in survivors, and deceased patients had more often not been treated (Table 2).  
 
Health-related quality of life  
Survivors showed significantly lower SF-36 scores, indicating a worse quality of life, than the reference 
group (Table 3). However, after adjustment for significant differences in background characteristics 
(i.e. age at survey, education, job and marital status, having children or not, and country of birth) only 
mental health remained significantly worse in survivors. This difference between survivors and the 
reference group was larger than the MID (Table 3). Mean STAI-6 anxiety scores were worse in 
patients than in the reference group (p <0.001 after correction for background variables). Among the 
survivors, 18% had a score above the cut-off value for being highly anxious, i.e. >44,23 vs. 15% in the 
reference sample. 
In the present study, cervical cancer-specific HRQoL scores were lower (indicating a better 
functioning) than in the validation study of the EORTC cervical cancer-specific module (QLQ-CX24).3 
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However, more symptoms were reported in the current study, e.g. crampy pain in the abdomen or 
belly (17%), urinary leakage (15%), lymphedema (17%), menopausal symptoms (18%), and 
neuropathy (15%). 
 
2-5- year vs. 6-10-year survivors 
Generic HRQoL was similar among the 2-5 and 6-10-year survivors (data not shown). STAI-6 scores 
were higher (indicating more anxiety) in the 2-5-year survivors (p=0.07). Cervical cancer-specific 
HRQoL differed only regarding body image (p=0.004) and sexual worry (p=0.04), which were worse in 
the 2-5-year survivors (Table 4). Univariate linear regression confirmed these findings.  
 
Primary radiotherapy vs. adjuvant radiotherapy after surgery vs. surgery only 
After correction for age at survey and disease stage at diagnosis and at follow-up, we compared three 
groups: primary radiotherapy (including chemoradiation), adjuvant radiotherapy after surgery, and 
surgery only. Generic HRQoL scores did not differ significantly between these groups (data not 
shown).  
Cervical cancer-specific function was worse in women treated with radiotherapy, e.g. symptom 
experience (p=0.006), sexual/vaginal functioning (p<0.001, but the numbers were small for this scale), 
and sexual worry (p<0.001) (Table 5), also for frequencies of reported symptoms per treatment group. 
Cervical cancer-specific HRQoL as reported after primary radiotherapy was worse than after adjuvant 
radiotherapy. The primary radiotherapy group consisted of women who received radiotherapy only 
(n=20) and of women who received chemoradiation, i.e. a combination of radiotherapy and 
chemotherapy (n=20). Comparing the treatment-specific HRQoL in these two groups, significant 
differences emerged for all but one of the EORTC QLQ-CX24 scale scores. The differences remained 
significant after controlling for differences in age at survey, and disease stage at diagnosis and at 
follow-up. Women treated by chemoradiation reported more symptom experience (p=0.001), body 
image (p=0.029), and sexual worry (p=0.004). However, women treated by radiotherapy only reported 
more lymphedema (p<0.001), peripheral neuropathy (p=0.01), and menopausal symptoms (p=0.01).  
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Discussion 
We assessed HRQoL in 291 cervical cancer survivors 2-10 years after diagnosis and treatment and 
found that the majority was doing well. However, cervical cancer-specific symptoms such as pain in 
the abdomen, urinary leakage, and menopausal symptoms were reported by several women and 
mental health was significantly worse than in the reference group. HRQoL scores of 2-5-year survivors 
were similar to those of the 6-10-year survivors except for more anxiety, worse body image and more 
sexual worry in the 2-5-year survival group. 
After correction for age and disease stage at diagnosis and at follow-up, treatment-related HRQoL was 
significantly worse after radiotherapy than after surgery only. This was in line with our hypothesis and 
with the earlier reported trend that radiotherapy is generally more associated with reduced HRQoL 
than surgery or chemotherapy.2, 26 Furthermore, more treatment-related symptoms were reported after 
primary radiotherapy than after adjuvant radiotherapy, a finding that did not correspond with our 
hypothesis. Half of the primary radiotherapy group had been treated with chemoradiation, the other 
half with radiotherapy only. We explored whether the high rate of treatment-related symptoms could be 
attributed to chemoradiation. Although we found significant differences between women treated by 
radiotherapy only vs. women treated by chemoradiation, one group was not overall worse than the 
other. We conclude that the high rate of treatment-related symptoms after primary radiotherapy can 
not be attributed to chemoradiation.     
Cervical cancer survivors had a lower level of education and less often had paid jobs than the 
reference group, indicating a less favorable socioeconomic status (SES) in survivors. This finding 
corresponds with earlier data on the association between cervical cancer and low SES. In American 
studies the incidence of cervical cancer was repeatedly found to increase with socioeconomic 
deprivation among all included ethnic groups (Asian and Pacific Islander, black, Hispanic, and 
white).27-29  
Our results confirm earlier findings in (mainly) small samples of long-term cervical cancer survivors. In 
a Swedish study among 46 cervical cancer survivors, 5-7 years after diagnosis, quality of life was 
satisfactory.7 Fifty-one US cervical cancer survivors (interviewed on average 8 years after diagnosis) 
were found to enjoy a good HRQoL, with physical, social, and emotional functioning comparable to or 
better than norm scores; however, in that study only 20% (51/254) of identified cervical cancer 
survivors completed the questionnaire.14 In another study reporting on 152 survivors of cervical or 
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endometrial cancer, diagnosed and treated on average 11 years earlier, HRQoL was found to 
approximate that of healthy controls, although cervical cancer survivors reported more negative 
mood.13 Data of 74 patients (37 treated with surgery and 37 with radiotherapy), on average 7 years 
after diagnosis, suggested that cervical cancer survivors who were treated with surgery alone can 
expect an overall quality of life and sexual function not unlike that of peers without a history of 
cancer.15 A recent large study among Korean cervical cancer survivors (n=860), diagnosed and 
treated 1.4-22 years earlier, showed that survivors reported more impaired social functioning, more 
bowel and urinary problems, and more menopausal symptoms than women from the general 
population12. As in our study, women treated by radiotherapy without surgery reported more peripheral 
neuropathy than others. Another corresponding finding was that women treated by radiotherapy 
experienced more sexual worry than women treated by surgery. Unfortunately, the response in this 
well-conducted latter study was only 12.4% (860 of 5943 potential subjects). The authors attribute the 
low response to the amount of time that passed since the cancer diagnosis, and the reluctance to 
provide personal information that is typical for Korean women12. 
In our study group, although generic HRQoL was relatively good several women reported treatment- 
related symptoms. Since the QLQ-CX24 module on cervical cancer-specific HRQoL has recently been 
published, we could compare our results with only two other studies: the EORTC validation study3 
itself, and the recent Korean study on HRQoL in cervical cancer survivors.12 The QLQ-CX-24 scores of 
our sample were better than those of the EORTC validation study, which may be explained by the 
EORTC sample partly consisting of patients in the primary treatment phase versus survivors at 2-10 
years after diagnosis in the current study. Except for menopausal symptoms, disease-specific function 
in our sample was also better than in the Korean sample, but we have no explanation for this 
difference. 
It may seem strange that an increased prevalence of treatment-related symptoms was not reflected in 
lower generic HRQoL scores in cervical cancer survivors. A relatively good generic HRQoL in 
combination with treatment-related side effects has also repeatedly been reported by men with 
prostate cancer.9, 30 Although these men considered treatment-related side effects to be a problem, 
they did not take them into account when completing HRQoL measures because they did not consider 
them to be aspects of health. Furthermore prostate cancer patients accepted treatment-related side 
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effects as an inevitable consequence of having been treated for cancer, a condition they perceived as 
life threatening.31 Similar processes may play a role in survivors of cervical cancer. 
The strengths of our study are the large number of respondents (n=291; response 69%), the 
population-based unselected sample of survivors reflecting average care in the general population in 
the Netherlands, the cooperation of all departments of gynecologic oncology in the region, and the 
availability of registry data on tumor characteristics at diagnosis and of therapy. An additional strength 
is the use of standardized, valid measures, including the new cervical cancer-specific module of the 
EORTC, the QLQ-CX24.3 Anxiety and cervical cancer-specific symptoms (e.g. lymphedema and 
menopausal symptoms) were assessed together with generic HRQoL, as was recommended in a 
recent review on quality of life studies of long-term survivors of cervical cancer.2  
Although the response rate of 69% in our study is reasonably good, our results can not necessarily be 
generalized to the whole group of cervical cancer survivors. Age, grade of differentiation at diagnosis, 
and time since diagnosis were similar in respondents and non-respondents. However, TNM stages 
were worse in the non-respondents and recurrences at follow-up were significantly more frequent in 
non-respondents than in respondents (4% vs. 1%).  
In 13% of respondents it was unknown whether metastases or recurrence had occurred, because their 
former gynecologists had not seen these women in recent years, and patient medical records 
contained no data on metastases or recurrence. The fact that a patient had not been seen by her 
treating physician may in itself be an indication that recurrence or metastasis probably had not 
occurred.  
On average, patients who had died at the time of the survey were older at diagnosis and had worse 
tumor characteristics than survivors. Survival is known to be worse in older women with cervical 
cancer, which is caused in part by the worse tumor stage at diagnosis.32 
The results of the present study may have implications for cost-effectiveness analyses of, for instance, 
programs for cervical cancer screening and HPV vaccinations. For such analyses HRQoL data are 
needed of women who survived cervical cancer, since the gains of preventing cervical cancer include 
the reduction of its incidence and thus a reduction of post-treatment phases in life. So far there is 
uncertainty with respect to the HRQoL associated with e.g. having invasive cancer.33 HRQoL effects 
as reported by survivors in this study can reduce this uncertainty. A clinical implication of the present 
study is that radiotherapy in general, and primary radiotherapy in particular, resulted in a higher 
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frequency of treatment-related side effects than surgery, information that is useful for clinicians and 
patients when faced with the choice of cervical cancer therapy.  
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Figure 1. Flow chart of the study population 
 
 
 
 
 
 
446 women (65%) still alive at 1st of January 
2006 
Participation of all departments of 
oncological gynecology of in the region 
444 women in cohort 
2 women died in January 2006 
421 women were sent a questionnaire 
15 addresses could not be verified, 8 
women were not addressed on their 
physician’s advice e.g. because of 
serious illness  
130 questionnaires not completed 
because of  changed address (n=12), 
women’s bad health (n=7), lack of 
motivation (n=3), personal circumstances 
(n=2), language problems (n=1) or for 
unknown reasons (n=105) 291 patients returned a completed 
questionnaire (response 69%) 
691 women diagnosed with cervical 
carcinoma between 1st of January 1995 and 
31st of December 2003, in the region of the 
Eindhoven Cancer Registry 
  
 
21 
Table 1. 
  Background variables of survivors, i.e. women diagnosed with cervical cancer in the years 
1995 - 2004 and alive at 1st of January 2006, and a reference group of women without cervical 
cancer randomly selected from the general population (n, %). The p-values indicate the 
significance level of differences between these groups. 
 Survivors  
n=291 
Reference group  
n=349 
p-value 
Age
 at time of the survey (years)   0.015 
 Average (SD) 52.9 (13.8) 50.5 (10.8)  
 Range 31-88 27-70  
    
Education 
  
0.003 
 Low education 115 44% 103 32%  
 Medium  118 45% 159 49%  
 High    29 11%   60 19%  
    
Job status  
 Paid job 
 
96 41% 
 
183 58% 
0.001 
 Housewife/unpaid job 83 37%   83 26%  
 No job 28 12%   20   6%  
 Retired 22 10%   29   9%  
    
Marital status
   
0.001 
 Married/cohabiting 188 66% 273 78%  
 Partner, but living alone   16   6%     8   2%  
 No partner   80 29%   68 20%  
    
Children 
   
 No   61 22%   48 15% 0.03 
 Yes 224 78% 279 85%  
 Average no. of children, range 2, 1-11 2, 1-7 0.013 
    
Country of birth    
 the Netherlands 261 92% 327 99% <0.001 
    
Country of birth of parents    
 Father born in the Netherlands 253 92% 316 99% <0.001 
 Mother born in the Netherlands 248 89% 311 99% <0.001 
 Both parents of non-Dutch descent 
 
  20   7%    2   1%  
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Table 2. 
 Clinical data of all women in the Southeast of the Netherlands who were diagnosed with 
cervical cancer in the years 1995-2004 (n, %), p-values relate to differences between 
respondents and non-respondents.  
  
Respondents 
(n=291) 
Non- 
respondents* 
(n=153) 
 
p-value 
Deceased 
patients** 
(n=247) 
Age
 at diagnosis (years)     
 Average (SD) 47 (14) 48 (14) 0.28 61 (18) 
 Range 25-83 15-81  24-100 
     
Years since diagnosis
   
 
 
 Average (SD) 6.6 (2.6) 6.8 (2.6) 0.29  
 Range 2.0-11.0 2-11   
     
Grade at diagnosis   0.51  
 1 Well differentiated  26  14% 10  11%  18 10% 
 2 Moderately differentiated  83  46% 44  48%  71 38% 
 3 Poorly differentiated  68  38%  38  41%  90 48% 
 4 Undifferentiated   3  2% -   9 5% 
 Missing   110        61          59 
 
    
TNM stage #
 at diagnosis (%)   0.37  
 0     1  -   1  1%  - - 
 1     204   71%   91  62%    51 22% 
 2      43  15%  27 18%    53 23% 
 3      35 12%  24 16%     67 28% 
 4         4    1%    4   3%    65 28% 
 missing            4       6           11   
 
 
 
    
Initial therapy
 (may contain several treatments per woman)   
Surgery  250  86% 121  79% 0.07 84 34% 
Radiotherapy    91  31%   57  37% 0.20 162 66% 
 External beam radiotherapy    83  29%   55  36% 0.11 155 63% 
 Internal radiotherapy    61  21%   37  24% 0.44 84 34% 
 Unknown form     5  2%    3  2% 0.86 8 3% 
Chemotherapy    29  10%  13  9% 0.62 37 15% 
No therapy     1  0%    1  1% 0.64 34 14% 
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Therapy-combinations 
  
0.23 
 
Surgery only 195  70%  93  61%  36 15% 
Surgery and radiotherapy   46  16%  25  16%  41 17% 
Surgery, radiotherapy and 
chemotherapy 
   5  2%   3  2%    6   3% 
Surgery and chemotherapy    4  1% -     1    0%-- 
Radiotherapy only  20  7%  20  13%  92 38% 
Radiotherapy and  chemotherapy  20  7%   9  6%  23 10% 
Chemotherapy only -   1  1%    7   3% 
No therapy     1  0%   1  1%  34 14% 
     
Metastases at follow-up
 (April 2006)  0.07 
 
  Yes   4 1%    2 1%   
  Unknown  38 13%   33 22%   
  No 249 86% 118 77%   
 
    
Recurrences at follow-up
 (April 2006)  0.001  
  Yes    2 1%   6 4%   
  Unknown   37 13%  34 22%   
  No 252 87% 113 74%   
*) non-respondents are women who did not return the questionnaire (n=130) or who were not          
addressed because lost to follow-up (n=15) or too ill according to their physician (n=8). 
**) deceased women were diagnosed with cervical cancer in 1995-2003 and were not alive   anymore 
at January 31st of January 2006. 
# TNM stage (Tumor-Node-Metastasis clinical classification) is identical to FIGO stage.  
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Table 3. 
 Observed generic quality of life scores (SD) of survivors, i.e. women diagnosed with cervical 
cancer in the years 1995 - 2004, and the reference group. The first column of p-values indicates 
the significance level of differences in observed scores, the second column of p-values indicates 
the significance level of differences in scores after controlling for differences in  age at survey, 
education, job and marital status, having children or not, and country of birth. 
 
 Survivors  
n=291 
Reference group  
n=349 
 
p-value 
p-value after controlling 
for differences in 
background variables 
SF-36 (0-100)     
Physical function 79.1 (26.1) 86.1 (18.6) <0.001 0.15 
Role-physical 73.0 (39.6) 82.7 (32.4) 0.001 0.38 
Bodily pain 83.4 (23.0) 85.1 (19.2) 0.33 0.34 
General health 68.2 (22.6) 71.3 (19.4) 0.07 0.80 
Vitality 63.9 (21.1) 68.0 (18.5) 0.011 0.35 
Social functioning 82.0 (22.3) 87.7 (17.8) 0.001 0.18 
Role emotional 80.8 (37.2) 88.2 (29.5) 0.007 0.50 
Mental health 67.4 (13.1) 79.3 (17.1) <0.001     <0.001  * 
     
EuroQol (0-100)     
EQ-5D utility score 81.4 (24.4) 87.5 (19.9) 0.001 0.38 
Valuation of own health 76.4 (19.6) 79.8 (12.9) 0.009 0.88 
     
Stai-6 (20-80) 36.0 (11.2) 37.7 (7.2) 0.025 <0.001    
 
SD = standard deviation . 
Higher scores indicate better functioning, except for Stai-6. 
*) Differences exceed the Minimal Important Difference (MID). 
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Table 4. 
 Disease-specific quality of life scores (SD) of women diagnosed with cervical cancer in the years 
1995 - 2004 and alive at January 1st, 2006, for the entire group of survivors who responded, 2-5 yrs 
survivors, and 6-10 yrs survivors respectively. P-values refer to differences between the last 2 
groups.  
 All survivors  
n=291 
2-5 yrs survivors 
n=126 
6-10 yrs survivors 
n=165 
 
p-value 
Age  
      Mean (Standard Deviation) 
 
52.9 (13.8) 
 
52.4 (13.9) 
 
53.4 (13.7) 
 
0.61 
     
EORTC QLQ-CX24 (0-100)     
Multi-item scales     
Symptom Experience   15.1 (14.1)  16.7 (14.6) 14.0 (13.7) 0.12 
Body Image   15.9 (23.9) 20.7 (26.4) 12.2 (21.2) 0.004 
Sexual/vaginal functioning  16.2 (22.3) 17.6 (24.4) 15.0 (20.5) 0.49 
Single-item scales     
Lymphoedema 18.5 (31.1) 15.2 (28.3) 21.1 (32.9) 0.13 
Peripheral Neuropathy 18.7 (28.3) 20.4 (31.3) 17.4 (26.0) 0.41 
Menopausal Symptoms  24.1 (31.3) 25.7 (34.9) 22.8 (28.3) 0.45 
Sexual Worry  13.8 (27.5) 17.9 (31.7) 10.7 (23.4) 0.04 
Sexual Activity  26.9 (26.4) 27.6 (25.1) 26.4 (27.4) 0.73 
Sexual Enjoyment  58.3 (30.1) 56.2 (30.8) 60.1 (29.5) 0.44 
 
Impact of Event Scale
 
    
Intrusion score (0-35) 6.3 (7.7) 6.9 (8.2) 5.8 (7.3) 0.25 
Avoidance score (0-40) 7.1 (8.5) 7.9 (8.5) 6.5 (8.5) 0.19 
Total distress score (0-75) 13.4 (15.0)  14.8 (15.6) 12.3 (14.4) 0.17 
 
Higher scores indicate worse functioning, except for Sexual Activity and Sexual Enjoyment. 
 
  
 
26 
Table 5. 
 Mean values (SD) of cervical cancer specific quality of life (assessed through EORTC QLQ-CX24) 
and frequency of treatment related symptoms in % of women that reported to have experienced 
them ‘quite a bit’ or ‘rather much’ during the week before completion of the survey. 
  
Therapy Primary 
radiotherapy # 
n=40 
Surgery 
only 
n=195  
Adjuvant radiotherapy 
after surgery 
n=46 
 
p-value## 
Age  
      Mean (SD) 
 
63.6 (15.9) 
 
49.6 (11.8) 
 
58.7 (14.9) 
 
<0.001 
     
Symptom Experience (0-100) 18.5 (16.2) 12.9 (12.8) 19.4 (13.9) 0.006 
Cramps in abdomen 24% 14% 21%  
Difficulty in controlling bowels 21% 6% 21%  
Blood in stools 3% 1% 2%  
Pass water/urine frequently 42% 24% 45%  
Pain or burning feeling when urinating 8% 3% 7%  
Leaking of urine 19% 10% 26%  
Difficulty emptying bladder 6% 10% 11%  
Pain in lower back 22% 24% 19%  
Irritation/soreness in vagina or vulva 5% 5% 7%  
Discharge from vagina 5% 7% 5%  
Abnormal bleeding from vagina 3% 1% 7%  
     
Body Image (0-100) 26.3 (30.6) 11.2 (19.4) 23.3 (28.2) 0.202 
Felt physically less attractive 24% 5% 18%  
Felt less feminine 18% 4% 16%  
Felt dissatisfied with body 34% 13% 25%  
     
Lymphoedema (0-100) 11.7 (27.5) 15.8 (28.8) 34.9 (37.1) 0.005 
Swelling in one or both legs 11% 13% 34%  
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Peripheral Neuropathy (0-100) 27.0 (29.2) 16.5 (26.3) 17.5 (30.6) 0.52 
Tingling or numbness in hands or feet 24% 12% 14%  
     
Menopausal Symptoms (0-100) 29.7 (37.5) 22.1 (30.3) 23.8 (26.8) 0.40 
Hot flushes and/or sweats 24% 19% 16%  
     
Sexual Worry (0-100) 
Worried that sex would be painful 
25.3 (39.1) 
27% 
7.8 (18.3) 
5% 
25.6 (35.4) 
26% 
<0.001 
 
 
    
Sexual Activity (0-100) *  13.3 (20.1) 31.4 (27.5) 17.1 (21.0) 0.12 
Sexually active in past 4 weeks?     
 Quite a bit or rather much 6% 29% 7%  
 A little 29% 37% 37%  
     
IF SEXUALLY  ACTIVE: n=11 n=115 n=20  
Sexual/vaginal functioning (0-100) 47.7 (30.3) 11.0 (16.6) 22.9 (25.3) <0.001 
Vagina felt dry during sexual activity (n, %) 5, 46% 15, 13% 5, 25%  
Inconvenience because vagina felt short (n, %) 6, 55% 4, 4% 2, 10%  
Inconvenience because vagina felt tight (n, %) 7, 64% 5, 4% 3, 15%  
Pain during sexual intercourse/activity (n, %) 4, 36% 3, 3% 4, 20%  
     
Sexual Enjoyment (0-100) *  36.4 (23.4) 63.3 (29.0) 50 (31.5) 0.06 
Sexual activity enjoyable? 3, 27% 82, 70% 10, 50%  
 
#) Primary radiotherapy: women treated by radiotherapy only or by radiotherapy and chemotherapy. 
##) p-value after correction for age at survey, and disease stage at diagnosis and at follow-up. 
Higher scale scores indicate worse functioning, except for Sexual Activity and Sexual Enjoyment. 
*) These scales do not represent ‘symptoms’. 
 
